Skip to main content

Advertisement

SpringerLink
Log in

Clinical factors of PICC-RVT in cancer patients: a meta-analysis

  • Review
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

There is a lack of studies that systematically evaluate the clinical factors of PICC-RVT such as treatment, tumor stage, metastasis, and chemotherapy drugs in cancer patients. This study, therefore, aims to evaluate the clinical factors of catheter-related venous thrombosis in cancer patients with indwelling PICC to provide a basis for the clinical prevention and reduction of thrombosis.

Methods

Relevant studies were retrieved from major databases (PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), WanFang Data, and China Biology Medicine disc (CMB)) and searched from their earliest available dates until July 2022. If two or more studies had the same outcome, a meta-analysis using RevMan 5.4.1 was performed. This systematic review was registered at PROSPERO (number CRD42022358426).

Results

A total of 19 articles involving 19,824 patients were included for quantitative analysis. Meta-analysis of these studies indicated that a history of chemotherapy, tumor type, tumor stage, presence or absence of metastasis, and use of fluorouracil, etoposide, platinum drugs, and taxane were all risk factors for PICC catheter thrombosis in cancer patients.

Conclusion

In clinical PICC catheter thrombosis prevention, patients with the above characteristics should be watched more closely than other patients, as they have a higher risk for PICC catheter thrombosis. Based on the present evidence at hand, radiotherapy cannot be considered to be related to the formation of PICC-RVT in cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

Data Availability

All relevant data are within the paper.

References

  1. Sun K, Zheng R, Zhang S et al (2019) Report of cancer incidence and mortality in different areas of China, 2015. China Cancer 28(01):1–11

    Google Scholar 

  2. Zheng R, Sun K, Zhang S et al (2019) Report of cancer epidemiology. Chin J Oncol 41(01):19–28

    CAS  Google Scholar 

  3. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin 68(6):394–424

    Google Scholar 

  4. Gorski LA, Hadaway L, Hagle ME et al (2021) Infusion Therapy Standards of Practice 8th Edition. J Infus Nurs 44(1S Suppl 1):1–224

    Google Scholar 

  5. Moss JG, Wu O, Bodenham AR et al (2021) Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. The Lancet 398(10298):403–415

    Google Scholar 

  6. Ou Y, Jiang H, Chen D et al (2016) Investigation and analysis of the application of infusion tools in a tertiary A tumor hospital. J Nurs Train 31(18):1695–1698

    Google Scholar 

  7. Chopra V, Anand S, Hickner A et al (2013) Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet 382(9889):311–325

    PubMed  Google Scholar 

  8. Jiang Q, Zhang J, Li X et al (2017) Nursing care in reservation of the catheters in eleven nasopharyngeal carcinoma patients with symptomatic thrombosis after implantation of double-lumen PICCs. Chin J Nurs 52(01):17–20

    Google Scholar 

  9. Yi X, Chen J, Li J et al (2014) Risk factors associated with PICC-related upper extremity venous thrombosis in cancer patients. J Clin Nurs 23(5–6):837–843

    PubMed  Google Scholar 

  10. Chopra V, Kuhn L, Ratz D, Lee A, Krein S (2014) Peripherally inserted central catheter-related deep vein thrombosis: contemporary patterns and predictors: reply. J Thromb Haemost 12(11):1944–1947

    CAS  PubMed  Google Scholar 

  11. Linnemann B, Lindhoff-Last E (2012) Risk factors, management and primary prevention of thrombotic complications related to the use of central venous catheters. Vasa 41(5):319–332

    PubMed  Google Scholar 

  12. Zhao R, Shentu Y, Chen C et al (2012) Observation and nursing of patients with peripherally inserted central catheters after the formation of catheter-related venous thrombosis. Chin J Nurs 47(11):1014–1016

    Google Scholar 

  13. Hingorani AP, Ascher E, Markevich N et al (2006) Prospective evaluation of combined upper and lower extremity DVT. Vasc Endovascular Surg 40(2):131–134

    PubMed  Google Scholar 

  14. Al-Asadi O, Almusarhed M, Eldeeb H (2019) Predictive risk factors of venous thromboembolism (VTE) associated with peripherally inserted central catheters (PICC) in ambulant solid cancer patients: retrospective single Centre cohort study. Thromb J 17:2

    PubMed  PubMed Central  Google Scholar 

  15. Aw A, Carrier M, Koczerginski J, Mcdiarmid S, Tay J (2012) Incidence and predictive factors of symptomatic thrombosis related to peripherally inserted central catheters in chemotherapy patient. Thromb Res 130(3):323–326

  16. Chen P, Wan G, Zhu B (2021) Incidence and risk factors of symptomatic thrombosis related to peripherally inserted central catheter in patients with lung cancer. J Adv Nurs 77(3):1284–1292

    PubMed  Google Scholar 

  17. Chen Y, Chen H, Yang J et al (2020) Patterns and risk factors of peripherally inserted central venous catheter-related symptomatic thrombosis events in patients with malignant tumors receiving chemotherapy. J Vasc Surg Venous Lymphat Disord 8(6):919–929

    PubMed  Google Scholar 

  18. Feng Y, Fu Y, Xiang Q et al (2021) Plasminogen activator inhibitor-1 gene promoter 4G/5G polymorphism and risks of peripherally inserted central catheter-related venous thrombosis in patients with lung cancer: a prospective cohort study. Support Care Cancer 29(11):6431–6439

    PubMed  Google Scholar 

  19. Feng Y, Zheng R, Fu Y et al (2021) Assessing the thrombosis risk of peripherally inserted central catheters in cancer patients using Caprini risk assessment model: a prospective cohort study. Support Care Cancer 29(9):5047–5055

    PubMed  Google Scholar 

  20. Jones D, Wismayer K, Bozas G et al (2017) The risk of venous thromboembolism associated with peripherally inserted central catheters in ambulant cancer patients. Thromb J 15(1):25

  21. Kang JR, Long LH, Yan SW et al (2017) Peripherally inserted central catheter-related vein thrombosis in patients with lung cancer. Clin Appl Thromb Hemost 23(2):181–186

    PubMed  Google Scholar 

  22. Kang J, Sun W, Li H et al (2016) Peripherally inserted central catheter-related vein thrombosis in breast cancer patients. J Vasc Access 17(1):67–71

    PubMed  Google Scholar 

  23. Liang YJ, He Y, Li JM et al (2018) The incidence and predictors of symptomatic venous thromboembolism associated with peripherally inserted central catheters in patients with nasopharyngeal carcinoma. Onco Targets Ther 11:3119–3127

    PubMed  PubMed Central  Google Scholar 

  24. Liu Y, Gao Y, Wei L et al (2015) Peripherally inserted central catheter thrombosis incidence and risk factors in cancer patients: a double-center prospective investigation. Ther Clin Risk Manag 11:153–160

    PubMed  PubMed Central  Google Scholar 

  25. Min C, Lili D, Yanli W, Huaying L, Xiuqin L (2022) Current status of occurrence, related risk factors and nursing interventions of PICC-associated venous thrombosis in patients with lung cancer chemotherapy. Acta Medica Mediterr 38(2):1009–1014

    Google Scholar 

  26. Wang G, Wang H, Shen Y et al (2021) Association between ABO blood group and venous thrombosis related to the peripherally inserted central catheters in cancer patients. J Vasc Access 22(4):590–596

    PubMed  Google Scholar 

  27. Yi XL, Chen J, Li J et al (2014) Risk factors associated with PICC-related upper extremity venous thrombosis in cancer patients. J Clin Nurs 23(5–6):837–843

    PubMed  Google Scholar 

  28. Zhang X, Huang JJ, Xia Y et al (2016) High risk of deep vein thrombosis associated with peripherally inserted central catheters in lymphoma. Oncotarget 7(23):35404–35411

    PubMed  PubMed Central  Google Scholar 

  29. Wang G, Shen Y, Dong J et al (2019) Predictive factors of thrombosis related to peripherally inserted central catheters in cancer patients. Parenteral Enteral Nutrition 26(06):331–336

    CAS  Google Scholar 

  30. Wang L, Tian J, Du L et al (2016) Influencing factors and nursing countermeasures of venous thrombus in tumour patients with PICC. Chin J Mod Nurs 22(21):2992–2995

  31. Yu R, Chen L, Zhou X et al (2016) The risk factors of thrombosis associated with peripherally inserted central catheters among cancer patients. Chinese Nurs Manage 16(10):1326–1330

    Google Scholar 

  32. Zhang Y, Cui Y, Qian Z et al (2016) Analysis of risk factors for PICC-related venous thrombosis in lung cancer patients. Chin J Nurs 51(04):434–437

    Google Scholar 

  33. Romano F, Di Lorenzo G, Stabile G et al (2022) A systematic review of the guidelines on venous thromboembolism prophylaxis in gynecologic oncology. Cancers (Basel) 14(10):2439

  34. Khorana AA, Mackman N, Falanga A et al (2022) Cancer-associated venous thromboembolism. Nat Rev Dis Primers 8(1):11

    PubMed  Google Scholar 

  35. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723

    CAS  PubMed  Google Scholar 

  36. Shen L, Zhang Z, Zhu B (2016) Clinical analysis of tumor related venous thromboembolism: 196 cases. Chin Oncol 26(04):338–345

    Google Scholar 

  37. Blom JW, Osanto S, Rosendaal FR (2004) The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2(10):1760–1765

    CAS  PubMed  Google Scholar 

  38. Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464

    PubMed  Google Scholar 

  39. Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9(7):e1001275

    PubMed  PubMed Central  Google Scholar 

  40. Haas SL, Jesnowski R, Steiner M et al (2006) Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 12(30):4843–4849

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Luo L, Wang G, Guo Q et al (2021) A clinical investigation of PICC-related upper extremity asymptomatic venous thrombosis in cancer patients. Chinese Nurs Manage 21(01):25–30

    Google Scholar 

  42. Lyman GH, Khorana AA, Falanga A et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490–5505

    CAS  PubMed  Google Scholar 

  43. Hao N, Xie X, Zhou Z et al (2017) Nomogram predicted risk of peripherally inserted central catheter related thrombosis. Sci Rep 7(1):6344

    PubMed  PubMed Central  Google Scholar 

  44. Nakayama M, Munemura Y, Kanaya N, Tsuchida H, Namiki A (2001) Efficacy of alkalinized lidocaine for reducing pain on intravenous and epidural catheterization. J Anesth 15(4):201–203

    CAS  PubMed  Google Scholar 

  45. Nelson AL (1995) Neutralizing pH of lidocaine reduces pain during Norplant system insertion procedure. Contraception 51(5):299–301

    CAS  PubMed  Google Scholar 

  46. Moore RA, Adel N, Riedel E et al (2011) High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29(25):3466–3473

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM (1993) In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 53(13):3028–3033

    CAS  PubMed  Google Scholar 

  48. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M (2003) Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol 42(4):304–308

    CAS  PubMed  Google Scholar 

  49. Jin Y, Heck DE, DeGeorge G, Tian Y, Laskin JD (1996) 5-Fluorouracil suppresses nitric oxide biosynthesis in colon carcinoma cells. Cancer Res 56(9):1978–1982

    CAS  PubMed  Google Scholar 

  50. Focaccetti C, Bruno A, Magnani E et al (2015) Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One 10(2):e0115686

    PubMed  PubMed Central  Google Scholar 

  51. Baerlocher GM, Beer JH, Owen GR, Meiselman HJ, Reinhart WH (1997) The anti-neoplastic drug 5-fluorouracil produces echinocytosis and affects blood rheology. Br J Haematol 99(2):426–432

    CAS  PubMed  Google Scholar 

  52. Seng S, Liu Z, Chiu SK et al (2012) Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol 30(35):4416–4426

    CAS  PubMed  Google Scholar 

  53. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A (2007) Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 5(12):2445–2452

    CAS  PubMed  Google Scholar 

  54. Monreal M, Falgá C, Valle R et al (2006) Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 119(12):1073–1079

    PubMed  Google Scholar 

  55. Chung SM, Bae ON, Lim KM et al (2007) Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 27(2):414–421

    CAS  PubMed  Google Scholar 

  56. Kim K, Chang YK, Bian Y et al (2018) Pro-coagulant and pro-thrombotic effects of paclitaxel mediated by red blood cells. Thromb Haemost 118(10):1765–1775

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank AiMi Academic Services (www.aimieditor.com) for English language editing and review services.

Author information

Authors and Affiliations

  1. School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical College, NO.9 Dong Dan San Tiao, Beijing, 100730, China

    Shengmiao Ma, Chen Shen, Qiuyue Li, Haojie Yang, Yule Hu, Xiaolei Wei & Tao Liang

Authors
  1. Shengmiao Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chen Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qiuyue Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haojie Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yule Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaolei Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tao Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Shengmiao Ma and Tao Liang designed the study. Shengmiao Ma, Chen Shen, and Qiuyue Li searched the literature, selected the studies, extracted the data, and conducted a quality assessment. Shengmiao Ma, Tao Liang, Haojie Yang, and Xiaolei Wei planned the analyses and conducted the meta-analysis. Shengmiao Ma drafted the manuscript. Yule Hu and Tao Liang contributed to subsequent versions of the manuscript. All authors have read and agreed to the publication of this version of the manuscript.

Corresponding author

Correspondence to Tao Liang.

Ethics declarations

Ethical approval

This meta-analysis received ethical approval from the Ethics Committee of the School of Nursing, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMCSUN-2022-28).

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, S., Shen, C., Li, Q. et al. Clinical factors of PICC-RVT in cancer patients: a meta-analysis. Support Care Cancer 31, 393 (2023). https://doi.org/10.1007/s00520-023-07855-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00520-023-07855-8

Keywords

Search

Navigation